Address: PO Box 222, Pymble BC NSW 2073,Australia
Tel:
The Generic Medicines Industry Association (GMiA) is a representative body of generic medicine suppliers in Australia. Its members ensure that all Australians are offered the highest quality generic medicines in the world whilst providing affordable community health outcomes that benefit all Australians.
The guiding principles of the members of GMiA are:
To support the long term sustainability of the PBS by ensuring the timely and cost effective provision of Generic Medicines to consumers.
To support the quality use of medicines (QUM) in partnership with other stakeholders.
To support the development of policies that facilitate timely access to Generic Medicines for all Australians.
To support the development of policies that promote the continued viability of a local manufacturing base for Generic Medicines (for domestic and export markets).
To encourage a high level of awareness and general knowledge of the safety, efficacy and appropriate interchangeability of Generic Medicines amongst Healthcare Professionals, Government and Consumers.
To support balanced intellectual property rights in the pharmaceutical sector that enable timely, cost effective access to Generic Medicines.
To enhance the accountability of Members by establishing a complaints handling mechanism that is both readily accessible and transparent.
To reduce actual and potential conflicts of interest between Members and Healthcare Professionals responsible for prescribing and dispensing prescription medicines by establishing an Educational Event reporting procedure with independent review.
In trying to be an effective association and positively influence the environment for your members, what have been the main achievements and milestones since you were appointed in 2008? We…
To begin, would you please introduce GMIA to Pharmaceutical Executive readers? The GMIA is an industry organization. Its six members are: Alphapharm, Apotex, Genepharm, Hospira, Sandoz and Sigma. The GMiA…
After last year’s acquisition of Vifor Pharma, the firm’s largest ever, opened new avenues for diversification, the ground-breaking approval of the Hemgenix gene therapy for Hemophilia B was an equally…
Shawview Consulting’s Brendan Shaw casts his eye over the increased industry focus on Environment, Social, and Governance (ESG) issues in recent years, urging pharma companies to deliver on their ESG promises…
Brendan Shaw looks ahead to the rest of 2023, identifying five key trends to watch out for in the healthcare and life sciences sector. With the worst of COVID-19 now…
CSL, Australia’s largest biopharma company, overcame the challenges of the pandemic-related decline in plasma collection and has since racked up wins such as the acquisition of Vifor, the largest in…
A roundup of some of the latest news from Australian pharma, including CSL’s unification of business units, a workers strike at Pfizer’s manufacturing plant, a new USD 173 million research…
Pharmaceutical policy issues played a major role in Australia’s recent national election. Shawview Consulting’s Brendan Shaw outlines the medicines issues that came under scrutiny during the campaign. It was the…
Writing in April edition of DIA’s Global Forum magazine, the University of New South Wales’s Richard Day looks at Australia’s National Medicines Policy (NMP) and how it is being reshaped…
Writing in the January edition of DIA’s Global Forum magazine, Julia Chan, David Liew, Jana Stojanova, and Chris McMaster of Austin Health, Melbourne and St. Vincent’s Hospital Sydney outline how…
In conversation in the November issue of DIA’s Global Forum magazine, Australian Pharmaceutical medical and scientific Professionals Association (APPA) Past President David Grolman highlights the contributions that Australia is already…
Regular PharmaBoardroom contributor Brendan Shaw outlines how his home country of Australia has so far successfully managed to avoid the worst of the COVID-19 pandemic, providing opportunities for the life…
In an exclusive new podcast, DIA Global Forum Australia/New Zealand Regional Editor Richard Day (University of New South Wales, Medicine, St. Vincent’s Hospital) and John Skeritt, Head of Australia’s Therapeutic Goods Administration (TGA),…
Janssen Australia & New Zealand’s Bruce Goodwin argues that greater adoption of patient-centric practices is beneficial to patients, companies and healthcare systems as a whole. Goodwin also gives his five…
See our Cookie Privacy Policy Here